Lifesci Capital Forecasts MBX Biosciences Q1 Earnings

MBX Biosciences, Inc. (NASDAQ:MBX) – Research analysts at Lifesci Capital issued their Q1 2026 earnings per share estimates for MBX Biosciences in a research note issued on Tuesday, March 31st. Lifesci Capital analyst P. Dolezal anticipates that the company will earn ($0.66) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. Lifesci Capital also issued estimates for MBX Biosciences’ Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.69) EPS.

Several other equities research analysts have also recently issued reports on the stock. Stifel Nicolaus lifted their price objective on shares of MBX Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Truist Financial set a $50.00 target price on shares of MBX Biosciences in a research note on Monday, March 9th. Barclays assumed coverage on shares of MBX Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of MBX Biosciences in a report on Thursday, March 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MBX Biosciences in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.56.

MBX Biosciences Price Performance

Shares of NASDAQ MBX opened at $32.99 on Friday. The company has a 50 day moving average of $33.31 and a 200 day moving average of $28.40. MBX Biosciences has a twelve month low of $4.81 and a twelve month high of $44.89. The firm has a market cap of $1.57 billion, a P/E ratio of -13.69 and a beta of 1.25.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.15.

Hedge Funds Weigh In On MBX Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new stake in MBX Biosciences in the fourth quarter worth $28,000. Russell Investments Group Ltd. grew its holdings in shares of MBX Biosciences by 4,131.4% in the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock worth $26,000 after purchasing an additional 1,446 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of MBX Biosciences by 59.6% in the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $49,000 after purchasing an additional 572 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in MBX Biosciences in the 3rd quarter worth about $27,000. Finally, California State Teachers Retirement System increased its stake in MBX Biosciences by 64.7% in the 4th quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock worth $55,000 after buying an additional 689 shares during the period.

Insiders Place Their Bets

In related news, CEO P. Kent Hawryluk acquired 18,500 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were acquired at an average cost of $28.41 per share, for a total transaction of $525,585.00. Following the completion of the transaction, the chief executive officer directly owned 486,777 shares in the company, valued at approximately $13,829,334.57. This trade represents a 3.95% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 52.19% of the stock is owned by insiders.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.